Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Sales

Burning Rock Biotech (BNR) EBITDA Margin: 2020-2024

Historic EBITDA Margin for Burning Rock Biotech (BNR) over the last 5 years, with Dec 2024 value amounting to 66.53%.

  • Burning Rock Biotech's EBITDA Margin rose 2064.00% to 13.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.15%, marking a year-over-year increase of 6515.00%. This contributed to the annual value of 66.53% for FY2024, which is 5432.00% up from last year.
  • As of FY2024, Burning Rock Biotech's EBITDA Margin stood at 66.53%, which was up 44.95% from 120.85% recorded in FY2023.
  • Burning Rock Biotech's EBITDA Margin's 5-year high stood at 66.53% during FY2024, with a 5-year trough of 165.10% in FY2022.
  • Its 3-year average for EBITDA Margin is 117.49%, with a median of 120.85% in 2023.
  • Per our database at Business Quant, Burning Rock Biotech's EBITDA Margin crashed by 2,878bps in 2021 and then skyrocketed by 5,432bps in 2024.
  • MRY analysis of 5 years shows Burning Rock Biotech's EBITDA Margin stood at 135.87% in 2020, then dropped by 21bps to 164.65% in 2021, then dropped by 0bps to 165.10% in 2022, then increased by 27bps to 120.85% in 2023, then skyrocketed by 45bps to 66.53% in 2024.
  • Its EBITDA Margin was 66.53% in FY2024, compared to 120.85% in FY2023 and 165.10% in FY2022.